Ascentage Pharma Group International
As of Oct 22, 2026, Ascentage Pharma Group International is in Stage 4, the downtrend phase, now in week 6 (since Sep 15, 2026). It closed at $14.92, 57.9% below its 52-week high and below its 200-day average, which is falling.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AAPG early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AAPG among Biotechnology384th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …384 | AAPG | Stage 4 · wk 6 | 20 | −4.2% |
Ascentage Pharma Group International: quick answers
What stage is Ascentage Pharma Group International in?
As of Oct 22, 2026, Ascentage Pharma Group International (AAPG) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 15, 2026 and is in week 6. What the four stages mean
Is Ascentage Pharma Group International in an uptrend?
No. Ascentage Pharma Group International is in a Stage 4 downtrend. It trades 27.4% below its 200-day average, which is falling.
How far is Ascentage Pharma Group International from its 52-week high?
Ascentage Pharma Group International closed at $14.92 on Oct 22, 2026, 57.9% below its 52-week high of $35.46. Its 52-week low is $14.55.
How has Ascentage Pharma Group International performed over the past year?
As of Oct 22, 2026, Ascentage Pharma Group International is down 56.7% over the past year and down 43.4% so far in 2026.
Which sector and industry is Ascentage Pharma Group International in?
Ascentage Pharma Group International is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.